Imunon, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMNN research report →
About the company
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications.
- CEO
- Stacy R. Lindborg
- IPO
- 1999
- Employees
- 25
- HQ
- Lawrenceville, NJ, US
Price Chart
- Market Cap
- $4.82M
- P/E
- -0.33
- P/S
- 0.00
- P/B
- 2.86
- EV/EBITDA
- -0.07
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -341.23%
- ROIC
- -346.77%
- Revenue
- $0 · 0.00%
- Net Income
- $-14,495,000 · 22.15%
- EPS
- $-6.83 · 67.63%
- Op Income
- $-14,650,694
- FCF YoY
- 24.93%
- 52W High
- $10.43
- 52W Low
- $1.70
- 50D MA
- $2.27
- 200D MA
- $3.44
- Beta
- 1.95
- Avg Volume
- 52.83K
Get TickerSpark's AI analysis on IMNN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Faller Douglas Vincent | other | 21,896 |
| Jun 25, 26 | Eylward Susan | other | 14,696 |
| Jun 29, 26 | Eylward Susan | sell | 11,800 |
| Jun 25, 26 | Tardugno Michael H | other | 42,519 |
| Jun 25, 26 | Lindborg Stacy | other | 67,150 |
| Jun 18, 26 | Tardugno Michael H | other | 4,629 |
| Jun 18, 26 | Lindborg Stacy | other | 1,803 |
| Jun 5, 26 | Tardugno Michael H | other | 4,089 |
| Jun 5, 26 | Lindborg Stacy | other | 1,593 |
| May 22, 26 | Tardugno Michael H | other | 3,484 |
Our IMNN coverage
Recent articles, reports, and earnings notes.
No research on IMNN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMNN report →Similar companies
Peers in the same neighborhood.